IMNM (Immunome) Scaled Net Operating Assets : -0.08 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunome Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Immunome's operating assets for the quarter that ended in Sep. 2024 was $16.77 Mil. Immunome's operating liabilities for the quarter that ended in Sep. 2024 was $39.27 Mil. Immunome's Total Assets for the quarter that ended in Jun. 2024 was $296.22 Mil. Therefore, Immunome's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -0.08.

Immunome Scaled Net Operating Assets Historical Data

The historical data trend for Immunome's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Scaled Net Operating Assets Chart

Immunome Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-8.46

0.43

-0.02

-0.06

-0.86

Immunome Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-2.03	-0.22	-0.15	-0.07	-0.08

Competitive Comparison of Immunome's Scaled Net Operating Assets

For the Biotechnology subindustry, Immunome's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Immunome's Scaled Net Operating Assets falls into.

Immunome Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Immunome's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(6.389	-	27.008)	/	24.046
=	-0.86

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	148.54	-	142.151
=	6.389

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	28.658	-	1.34	-	0.31
=	27.008

Immunome's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(16.768	-	39.271)	/	296.215
=	-0.08

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	256.898	-	240.13
=	16.768

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	41.992	-	2.464	-	0.257
=	39.271

Immunome Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Immunome's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunome Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011

Website

https://www.immunome.com

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Executives

Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Robert Lechleider	officer: Chief Medical Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett	officer: SVP Operations	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Jean Jacques Bienaime	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Higgins	officer: Chief Scientific Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas	director, other: See remarks	1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner	officer: Chief Strategy Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson	officer: Chief Technology Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp	director, 10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast	director
Michael Lefenfeld	director	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma	director, officer: President and CEO	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim	director	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019